Evidence map›Paper›PMID 40932605›Full record

SynthesisJournal of cancer research and clinical oncology2025

Molecular signatures of breast cancer in the Iranian population: a review of cell growth and cell cycle regulators.

Zeynab Mashayekh, Jalal Vallian Broojeni, Rasool Fatehi Fard, Sadeq Vallian

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zeynab MashayekhDepartment of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran.
Jalal Vallian BroojeniDepartment of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran.
Rasool Fatehi FardDepartment of Surgery, Isfahan University of Medical Sciences, Isfahan, Iran.
Sadeq VallianDepartment of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran. svallian@sci.ui.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mortality rate of breast cancer remains relatively high in the Iranian population, with approximately 4810 deaths reported in 2020 (GLOBOCAN). This elevated fatality rate has been predominantly attributed to delays in diagnosis. In recent years, substantial research efforts have been directed toward elucidating cellular markers associated with breast cancer within this population. To this end, a systematic literature search was undertaken across both international and national databases, including PubMed, Scopus, IranMedex, and Magiran, covering the period from 2019 to 2024. The review synthesized data from studies encompassing a total of 15,318 Iranian breast cancer patients. The aggregated evidence provides comprehensive insights into cellular growth and cell cycle regulation markers implicated in breast cancer, thereby offering potential to inform the development of population-specific molecular diagnostic and prognostic strategies.

Indexed as

Biomarkers, TumorBreast NeoplasmsCell CycleCell Cycle ProteinsCell ProliferationFemaleHumansIranPrognosisBiomarkers, TumorCell Cycle ProteinsBreast cancerCell cycleCellular growthIranian populationMolecular markers

Identifiers

PMID40932605
PMCPMC12426308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.